Check Out Marc Boutin's LinkedIn Stats (Last 30 Days)

Patient engagement is no longer just best practice—it’s a strategic imperative driving innovation, better outcomes, and stronger businesses. I’m excited to join Gilde Healthcare as an Advisor, supporting their mission to advance better care at lower cost by ensuring patient perspectives shape investment strategies and drive healthcare transformation. With a career spanning patient advocacy, healthcare policy, and corporate leadership—including as CEO of the National Health Council and Global Head of Patient Engagement at Novartis—I’ve worked to ensure that the patient voice drives meaningful change. Now, I look forward to helping Gilde Healthcare unlock value and drive innovation in healthcare through patient engagement—because solutions designed with and for patients lead to better outcomes, stronger health systems, and smarter investments, accelerating what’s possible. The future of healthcare belongs to those who put patients at the center. Let’s build it together. Nicholas Brooke Hayley Chapman Jan Geissler Zack Pemberton-Whiteley Joep Muijrers Annie Kennedy #PFMD #PatientEngagement #HealthcareInvestment #Innovation #Impact #BetterCareLowerCost

Peter Drucker famously said, “what gets measured gets improved.” As a patient advocate, I have long encouraged the pharmaceutical sector to improve patient engagement by doing more than just counting activities. More recently, as a global head of patient engagement, I asked my team to create a framework to assess and measure the value of patient engagement to patients, healthcare systems and our shareholders so that we could continuously improve. Check out this call to action to apply impact measurement to patient engagement: https://rdcu.be/dT9Ko The framework shows how metrics can be used to evaluate inputs, outputs, and the value of patient engagement across the medicines lifecycle. It was co-created with patient advisors in the context of systems and processes at Novartis but designed to be adaptable for any pharmaceutical company. A special thank you to Beyza Klein who led our efforts and to my former teammates, patient advisors and co-authors on this groundbreaking publication: Eleanor Perfetto, Elisabeth Oehrlein, PhD, MS, Fay Weston, Trudie Lobban MBE FRCP, Zack Pemberton-Whiteley, Jean-Pierre Malkowski, Nigel Breakwell, Zoe Healey #PatientEngagement, #PatientInvolvement, #SocialImpact, #ImpactMeasurement, #PEOF, #PFMD, #ShareholderValue

Robert Frost famously wrote, “two roads diverged in a wood, and I took the one less traveled … and that has made all the difference.”   Four years ago, I took the road less traveled and left the patient advocacy community to lead the patient engagement team at Novartis.   As a patient advocate, family caregiver and patient, I know first-hand that living your best life possible requires a difficult balance between how you feel, your ability to function and how long you will survive. Understanding the burden of disease and burden of treatment is critical to making and delivering medicines that address the outcomes that matter most to patients.   I joined Novartis to create and implement an enterprise-wide strategy covering all therapeutic areas to ensure consistent and systematic patient engagement across the lifecycle of medicines development.   In addition to developing mutually beneficial strategic partnerships with patient organizations around the world, my team embedded patient engagement in key processes such as the Target Product Profile, Integrated Evidence Plan and Clinical Evidence Plan. Through change management, strategic governance, capability building and impact measurement they demonstrated that patient engagement is not just good for patients – it is also good for business.   While I cannot list everyone at Novartis who joined me on the road less traveled, I want to give a special shoutout to: Michaela Dinboeck, Cornelia Hollinger, Jean-Pierre Malkowski, Begoña Gomez, Beatrice Baudino, Jacqueline Rosenberg, Zack Pemberton-Whiteley, Preya Patel, Manuel Haidlauf, Irini Chaviara, David Parrish, Conny Berlin, Monia Steenackers, Dabrowka Franquelin, Beyza Klein, Annekatrin Krause, Dawn Aubel, EdD, Alexey Salamakha, Flavia Perna 🇧🇷 🇨🇭 🇺🇸, Angels Costa Ferrer, Jean-Noel Talabardon, Katy Pountney; Magdalena Borowiec - Di Leo, Fiona H. Marshall, Shreeram Aradhye, Victor Bultó, Marie-France Tschudin, Klaus Moosmayer, Michelle Weese, Federica Castiglione, Jessica DiPaolo, MPH, Gonzalo Linares, Veronica Foote, Geoff Cook, David Palacios, M.D. MHA, Amber Spierer, MPH, Alissa Jaffe Nagler and so many more!   It has been a privilege to collaborate with you all – it has made all the difference.   As you continue your journeys at Novartis and beyond, I look forward to watching your impact grow exponentially. Patients and their family caregivers are counting on you.   Lastly, I would like to thank Laura McKeaveney my predecessor and the godmother of patient engagement at Novartis as well as Michael Willi former Chief Communications Officer and Vas Narasimhan our CEO for taking a leap of faith and asking a patient advocate to create a Patient Engagement function at Novartis.   It’s now time to find my next adventure on yet another road less traveled.   #PatientEngagement #PEIM #PatientInvolvement #PatientExperience #Change #Impact #Measurement #Patient #PFMD #PEOF

Patient centricity means creating medicines with - not for people living with chronic diseases and their family caregivers.

Engaging patients across the lifecycle of medicines development ensures that treatments address the outcomes that matter most to people living with disease. It also benefits business, investors and society. In the most recent Novartis investor update, I share some thoughts about integrating patient engagement into our core business processes and the impact on ESG in my capacity as the Global Head of Patinet Engagement. https://lnkd.in/ePD3ws6T #PatientEngagement #ESG #Access Nicholas Brooke Randall Rutta Esther Krofah Tanisha Carino Margaret Anderson (she/her)